Expert RA upgraded PROMOMED DM's credit rating to ruA
12.08.2025
Corporate
For investors
12.08.2025
Revenue growth by 82%[1], 5.5 times higher than the market growth rate – PROMOMED announces operational results for the 1st half of 2025
August 12, 2025, Moscow – PJSC PROMOMED (MOEX: PRMD) (formerly –PROMOMED", the "Company", and together with its subsidiaries, the "Group") announces the Group's operating results for the six months ended June 30, 2025.
OPERATIONAL INDICATORS
- In the reporting period, PROMOMED launched:
o The innovative drug Tirzetta® (INN tirzepatide), designed for the treatment of obesity and type II diabetes mellitus. Tirzetta® is the only direct competitor to the U.S.–registered and designated Mounjaro on the Russian market.
o The drug Apalutamide-Promomed (INN apalutamide) for the treatment of two types of prostate cancer is the first domestic second–generation androgen receptor inhibitor. In 2023, prostate cancer in Russia became the 1st most common cancer in men and the 3rd leading cause of cancer death. The cost of the drug is 40% lower compared to foreign analogues.
o The drug Velgia® Ivf (INN semaglutide) for the treatment of overweight and obesity, which is free of phenol, benzyl alcohol and other preservatives, which makes it available to patients with hypersensitivity or various liver and kidney diseases.
- The company continues to demonstrate growth rates that significantly outpace the growth rates of the pharmaceutical market.:
o In Q1 2025, according to management reports, the Company's revenue increased by 82% compared to Q1 2024, while the pharmaceutical market grew by 14.9% over the same period, according to IQVIA.
o In 1Q 2025, the evolution index[2] of the Endocrinological Portfolio was 120.9 (outstripping the growth of the relevant market of 9 INN by more than 20 percentage points).
o In Q1 2025, the index of the evolution of the Oncological Portfolio was 233.0 (ahead of the growth of the relevant 29 INN market by 133 percentage points). This result reflects the high demand for the Company's drugs and confirms the strategic importance of this therapeutic area.
o In 1Q 2025, the evolution index for Other drugs in the Base Portfolio was 131.2 (outstripping the growth of the relevant 169 INN market by more than 31 percentage points).
- In 1H 2025, the Company conducted 56 medical studies.
- In January 1, 2025, the Company received registration certificates for 15 medicines.
- In January 1, 2025, the Company registered 12 new patents. The increase in the number of intellectual property objects reflects the commitment of the ongoing strategy to bring innovative drugs to the market and confirms the steady expansion of the intangible asset portfolio.
FINANCIAL INDICATORS
- According to management reports, in Q1 2025, the Company's revenue increased by 82% to RUB 13.0 billion, compared with RUB 7.1 billion in Q1 2024.
- The share of revenue from the sale of innovative products increased to 60%, which is 3 percentage points higher than a year earlier (57% for 1Q 2024).
- The share of Endocrinological and Oncological portfolios in revenue for the 1st quarter of 2025 increased by 20 percentage points and amounted to 74% (54% for the 1st quarter of 2024), which is primarily due to the launch of new drugs on the market.
- The company continues to focus on the most promising segments of the pharmaceutical market:
o In the Endocrinology segment, revenue for the 1st quarter of 2025 increased by 118% compared to the 1st quarter of 2024 and amounted to 4.8 billion rubles, primarily due to the successful sales of new products – Quincenta®, Velgia® and Tirzetta®.
o In the Oncology segment, revenue for the 1st quarter of 2025 increased by 188% compared to the 1st quarter of 2024 and amounted to 4.7 billion rubles. The main growth driver was the introduction of new drugs to the market.
- The company confirms its financial forecast for 2025: revenue growth of 75% with an EBITDA margin of 40%.
"PROMOMED demonstrates the impressive success of implementing a growth strategy based on deep scientific expertise, a powerful production platform and effective operational activity in marketing and sales.
A systematic vision of the real needs of the pharmaceutical market and accumulated practical experience allow us to thoughtfully focus on strategically important areas, to launch the most modern solutions to the market that meet the current challenges of clinical practice and the demands of the healthcare system.
We carefully work out what has been planned and announced, and we value the trust of the professional community, our partners and investors."
About the Company
PJSC PROMOMED is a leading innovative biopharmaceutical company with the potential for significant growth in promising segments of the pharmaceutical market. In 2025, PROMOMED celebrates the 20th anniversary of the Company's founding.
The Company's structure includes its own unique world-class R&D center and a high–tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines. The company develops a diversified portfolio of more than 350 medicines in the TOP 10 segments of the pharmaceutical market. The Company's portfolio includes "blockbuster" drugs and innovative biotechnological drugs that have no analogues on the Russian market. Based on its own developments, the Company produces drugs for the treatment of socially significant diseases: oncology, diabetes, obesity, neurology, infectious diseases, rheumatology, etc. Thanks to its own innovative chemical technologies and biotechnologies, as well as modern production facilities, the Company is an active participant in the system of ensuring national drug safety and import independence of the country.
Contacts
|
For investors |
For the media |
This message and the information contained therein are not:
- an offer to purchase any securities,
- an invitation to make offers to purchase any securities,
- as part of such offers or invitations,
- advertising of securities in the Russian Federation or other jurisdictions,
- an offer to purchase medicines,
- advertising of medicines,
- by encouraging or recommending transactions,
- and is also not subject to interpretation as such.
Neither this communication nor any part of it is the basis for concluding any transaction or incurring any obligation, they cannot be used in connection with any transactions or obligations or serve as an incentive to conclude any transactions or assume any obligations.
Neither this announcement nor any part of it should serve as a basis for making any investment decisions and/or decisions on the use of any medicines.
The publication of this communication does not imply investment consulting (in the meaning defined in the legislation of the Russian Federation (including Federal Law No. 39-FZ of April 22, 1996 "On the Securities Market"). The information provided in this message is not an individual investment recommendation, and the financial instruments or transactions mentioned in it may not meet your investment profile and investment goals (expectations). It is your task to determine whether a financial instrument or operation matches your interests, investment goals, investment horizon, and acceptable risk level. PJSC PROMOMED is not responsible for possible losses in the event of transactions or investments in financial instruments mentioned in this information, and does not recommend using this information as the only source of information when making an investment decision.
Before making an investment decision on making or not making transactions with the Company's shares, it is necessary, among other things, to familiarize yourself with the information disclosed on the Company's web page https://e-disclosure.ru/portal/company.aspx?id=38533.
The information contained in this announcement may include estimates and other forward-looking statements regarding the intentions, plans, future events, financial, operational or other activities of the Group. Actual events, calculations and results of their activities may differ materially from those contained or anticipated in the forward-looking statements, words and expressions provided in this communication or related materials due to the influence of various external and internal factors (general economic conditions; risks associated with the specifics of the Company's activities, including those that cannot be controlled by the Company; changes in market conditions in the industry in which the Company and the Group operate; geopolitical and other factors and risks). An indication of goals, potential, growth opportunities or other indicators is not a guarantee of the realization of these goals, potential, opportunities.
The methodology for determining and calculating the operational and financial indicators of a Company may differ from the methodology used by other individuals, companies or organizations.
The Company or persons belonging to the Group, their directors, participants (shareholders), employees, representatives do not provide any guarantees or assurances confirming the accuracy, completeness or unambiguous nature of the information and information contained in this communication or related materials, and do not assume any obligations or obligations to updating them.
[1] Hereafter: financial indicators according to management reporting data.
[ 2] Evolution Index (EI) is an evolution index calculated to assess the progress of a product and/or a company's product portfolio in the market, reflecting the growth rate of a product compared to the growth of its relevant market. Values above 100 indicate by how many percentage points a product or portfolio is growing faster than the market
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office
